Congress Asked to Investigate Genentech’s Specialty-Drug Switch

by Admin | November 14, 2014 11:10 am

November 14, 2014—Ten of the nation’s leading academic medical centers have asked Congress to investigate Genentech’s decision to move the world’s three top-selling cancer drugs into the more expensive specialty distribution channel.  

You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register[1].    Already registered? Click here to login[2]. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)

Endnotes:
  1. Click here to register: https://secure.340bhealth.org/340Binformed/Subscribe.aspx
  2. Click here to login: http://340binformed.org/reader-login/

Source URL: https://340binformed.org/2014/11/congress-asked-to-investigate-genentechs-specialty-drug-switch/

Copyright ©2026 340binformed.org unless otherwise noted.